CGEMCullinan Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 13317
Ticker: CGEM
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2021-01-08
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CGEM

Detail

Enriched 2026-08-14 20:47

Market cap: $1,261,352,002.4
Shares outstanding (class): 64,354,694
Shares outstanding (weighted): 64,354,694
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 109
Location: CAMBRIDGE, MA
Homepage: https://www.cullinantherapeutics.com
Description: Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Market cap and share counts drift.

Funds holding this security

88 funds · 88 positions · $124.87M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$26.37M	0.00%	1,855,966 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$18.69M	0.03%	1,315,583 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$18.58M	0.25%	1,307,461 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$9.76M	0.09%	686,764 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$8.10M	0.01%	569,801 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$6.54M	0.05%	460,225 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$6.03M	0.05%	424,028 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$4.60M	0.06%	323,429 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$4.23M	0.05%	297,800 NS	FIGI
College Retirement Equities Fund - Total Global… College Retirement Equities Fund	—	$2.36M	0.00%	166,024 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$1.93M	0.16%	135,995 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$1.17M	0.02%	82,104 NS	FIGI
JPMorgan Small Cap Value Fund JPMorgan Trust II	—	$1.16M	0.10%	81,610 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.00M	0.00%	70,531 NS	FIGI
Fidelity Small Cap Value Index Fund Fidelity Salem Street Trust	—	$951.4K	0.05%	66,950 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCGEM
FIGI_COMPOSITEBBG00HW2DGQ4
FIGI_SHARE_CLASSBBG00HW2DGR3
CIK0001789972
ISINUS2300311063
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Cullinan Therapeutics is a biopharmaceutical company developing targeted therapies, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.